Dosing and Administration Challenges for Patients with Multiple Myeloma:
Understanding the Problem, Finding Solutions

Illinois Society of Health-System Pharmacists
Saturday, September 15, 2012 ~ 6:30am – 8:30am
Drury Lane Theater, Oakbrook Terrace, IL

Program Description

The 2 and 3 drug regimens commonly used to treat patients with MM usually contain one or more of the available novel agents, thalidomide, lenalidomide, and bortezomib, as well as one or more of older agents, such as dexamethasone, melphalan, prednisone, or cyclophosphamide. The dosing and administration of these regimens are defined in clinical trials, and dose adjustment recommendations for individual patient- and therapy-related factors are clear in a single agent's prescribing information. However, most patients present with co-morbidities, often with more than one, and are taking other medications for these conditions. In addition, individual patients react differently to various agents and there is no standard sequencing of agents and regimens. In other words, there is no "cookie-cutter" patient. As novel regimens and new agents and formulations enter the clinical arena, the oncology pharmacist must ensure that patient- and therapy-related factors, such as renal and liver function, comorbidities, and drug interactions, are recognized in order to appropriately manage the administration and dosing of a particular agent or regimen at any time in the life-cycle of the disease.

The case-based format of this CE activity will lay the foundation for understanding the rationale behind current recommendations in dosing and administration management as well as strategies for adverse event management that will optimize outcomes for patients with MM. Working through case vignettes with expert faculty support and recommendations will give participants a basis for applying dosing and administrative solutions to challenging cases they will experience in their own practice and apply new information to their own patients.

Learning Objectives

- For newly diagnosed patients, identify initial dose adjustments that are required based on patient- and disease-associated factors for all drugs in the chosen regimen to ensure maximum efficacy and tolerability
- Assess the pharmacokinetics and pharmacodynamics of emerging agents when integrating these agents into treatment regimens
- Evaluate adverse event management strategies for patients with MM receiving novel therapies and multi-drug regimens

Target Audience

This knowledge-based activity was developed for health system and oncology pharmacists as well as pharmacy technicians who wish to enhance their competence concerning regional/system variations in the delivery of care for patients with Multiple Myeloma.

Dosing and Administration Challenges for Patients with Multiple Myeloma:
Understanding the Problem, Finding Solutions

Illinois Society of Health-System Pharmacists
Saturday, September 15, 2012 ~ 6:30am – 8:30am
Drury Lane Theater, Oakbrook Terrace, IL

Faculty

Shawna Kraft, PharmD, BCOP
Clinical Pharmacist Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan Health System
Ann Arbor, MI

Kathryn Schultz, PharmD, BCPS, BCOP
Clinical Specialist, Hematology/Oncology
Rush University Medical Center
Chicago, IL

Agenda

6:30am – 7:00am	Breakfast & Registration
7:00am – 7:10am	Welcome & Introductions
7:10am – 7:30am	Multiple Myeloma 101 Newly-Diagnosed Patient/Multi-drug Regimen (ASCT eligible)
7:30am – 7:55am	Emerging Therapeutics and Administration Challenges
7:55am – 8:20am	Administration Challenges, Adverse Effect Management and Comorbidities: Personalized Medicine in Multiple Myeloma
8:20am – 8:30am	Question-and-Answer Session

Accreditation and Designation

Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.5 contact hours (0.1.5 CEUs) of continuing education credit. The universal program number for this activity is 0468-9999-12-004 L01P.

Acknowledgement

This activity is supported by an educational grant from Millennium: The Takeda Oncology Company.

This activity is jointly sponsored by Medical Learning Institute, Inc., a nonprofit medical accreditation company, and Center of Excellence Media, LLC.